Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism

This study has been terminated.
(Low subject recruitment and enrollment.)
Information provided by:
Northwestern University Identifier:
First received: August 28, 2008
Last updated: April 18, 2011
Last verified: April 2011

Parkinson's disease (PD) is the second most common neurodegenerative disorder of the elderly that affects a million patients in US. Sleep dysfunction impacts up to 90% of PD patients. PD patients experience a variety of sleep disorders including parasomnias, specifically REM behavior disorder (RBD) that can precede the onset of motor manifestations of PD. RBD has negative consequences on patients' and their bed partners' quality of life mainly due to its impact on the sleep quality and day time alertness. RBD also predisposes affected individuals and their bed partners to physical injuries.

There are no FDA approved treatments for RBD. Clonazepam is the most commonly used treatment but carries risks of daytime sedation, tolerance, and withdrawal symptoms. More recently, melatonin has been demonstrated to be effective in several small studies. Ramelteon, a selective melatonin receptor agonist with favorable safety profile, could potentially be effective for the treatment of RBD.

This pilot protocol will investigate safety and efficacy of ramelteon for the treatment of RBD in subjects with parkinsonism. We plan to recruit 20 subjects with RBD diagnosed based on the clinical interview and confirmed by the polysomnographic (PSG) data. The study is designed as a prospective randomized placebo controlled 12-week study. Primary outcome measure will be change in frequency of RBD events based on the daily sleep diaries. Secondary outcome measure will be change in the amount of tonic muscle activity based on the results of the baseline and final PSG. A number of other secondary and exploratory outcome measures will be collected

Condition Intervention
REM Behavior Disorder
Drug: Rozerem
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Tolerability of Ramelteon in Patients With REM Behavior Disorder and Parkinsonism: A Placebo Controlled, Double Blind, Randomized, Prospective Pilot Study

Resource links provided by NLM:

Further study details as provided by Northwestern University:

Primary Outcome Measures:
  • Change in the Frequency of RBD Based on the Daily Sleep Diaries, Completed Daily for the Duration of the Study by the Study Subjects' Bed Partners/Caregivers [ Time Frame: 12 weeks ]

    Change in the frequency of RBD based on the daily sleep diaries, completed daily for the duration of the study by the study subjects' bed partners/caregivers.

    Data will not be analyzed. The protocol is being terminated due to low subject enrollment and recruitment.

Secondary Outcome Measures:
  • Change in the Amount of Tonic Muscle Activity Based on the Results of the Baseline and Final Polysomnographic (PSG) Study [ Time Frame: 8 weeks ]
  • Changes in Mean TST, LPS, WASO (Based on PSG) [ Time Frame: 8 weeks ]
  • Changes in Clinician Global Impression Scale of Improvement (CGI-I) [ Time Frame: 10 weeks ]
  • Changes in RBD Structured Questionnaire (Completed by Patient and Bed Partner) [ Time Frame: 12 weeks ]
  • Changes in Patient Completed Parkinson's Disease Sleep Scale (PDSS)- the Only Validated PD Specific, Questionnaire-based, Sleep Evaluation Scale [ Time Frame: 12 weeks ]
  • Changes in Patient Completed Epworth Sleepiness Scale (ESS) [ Time Frame: 12 weeks ]
  • Changes in Beck Depression Inventory (BDI) [ Time Frame: 12 weeks ]
  • Changes in Pittsburgh Sleep Quality Index (PSQI) (Patient Completed) [ Time Frame: 12 weeks ]
  • Changes in Patient Completed The Fatigue Severity Scale (FSS) [ Time Frame: 12 weeks ]
  • Changes in Patient Completed PDQ-39 Scale(PD-specific Quality of Life Scale) [ Time Frame: 12 weeks ]
  • Changes in Physician Completed United Parkinson's Disease Rating Scale (UPDRS) [ Time Frame: 12 weeks ]
  • Changes in Mini-Mental State Exam (MMSE) [ Time Frame: 12 weeks ]
  • Changes in The Montreal Cognitive Assessment Scale (MoCA) [ Time Frame: 12 weeks ]
  • Study Terminated Due to Low Subject Recruitment and Enrollment.
    Low subject recruitment and enrollment

Enrollment: 3
Study Start Date: June 2008
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Ramelteon (TAK-375) 8mg tablets
Drug: Rozerem
Subjects take 1 8mg tablet 30 minutes before bedtime everyday for 8 weeks.
Other Names:
  • Ramelteon
  • TAK-375
Placebo Comparator: 2
Placebo 8 mg tablets
Drug: Placebo
Placebo 8 mg tablets

Detailed Description:
See above.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of parkinsonism (idiopathic PD, multiple systems atrophy, Lewy body dementia)
  • RBD frequency of at least once per week based on the RBD screening clinical questionnaire
  • PSG evidence of RBD
  • Presence of bed partner/caregiver who sleeps in the same room as PD patient

Exclusion Criteria:

  • Known hypersensitivity to ramelteon or related compounds, including melatonin and melatonin-related compounds.
  • Use of hypnotics or other sedatives within a month prior to the study initiation
  • Presence of active psychosis
  • Use of neuroleptics, except for the atypical neuroleptics - specifically quetiapine (the dose should not exceed 50mg/day)
  • Use of antidepressants unless the patient has been on a stable dose for at least three months
  • Use of Venlafaxine (Effexor®)
  • Presence of cognitive impairment, defined as the Mini Mental Status Examination (MMSE) score <24
  • Presence of depression defined as the Beck Depression Inventory (BDI) score >14
  • Significant sleep disordered breathing (defined as an apnea-hypopnea index>15 events/hr of sleep on screening PSG), significant periodic limb movement disorder (defined as a PLM index>10 events/hr of sleep with awakening on screening PSG)
  • Travel through two time zones within a month prior to the study initiation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00745030

United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Northwestern University
Principal Investigator: Tanya Simuni, M.D. Northwestern University, Department of Neurology
Study Director: Aleksandar Videnovic, M.D. Northwestern University, Department of Neurology
  More Information


Responsible Party: Tanya Simuni, MD, Northwestern University Identifier: NCT00745030     History of Changes
Other Study ID Numbers: 07-028R
Study First Received: August 28, 2008
Results First Received: October 12, 2010
Last Updated: April 18, 2011

Keywords provided by Northwestern University:
Parkinson's disease
Multiple Systems Atrophy
Lewy Body Dementia

Additional relevant MeSH terms:
Parkinsonian Disorders
Mental Disorders
REM Sleep Behavior Disorder
Pathologic Processes
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
REM Sleep Parasomnias
Sleep Wake Disorders processed this record on April 21, 2017